Menu

B. De Prijck MD

Articles

O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

BJH - volume 5, issue Abstract Book BHS, january 2014

M. André MD, B. De Prijck MD, A. Kentos MD, A. Van Hoof MD, PhD, C. Bonnet MD, PhD, A. Sonet MD, M. Maerevoet MD, E. Van den Neste MD, PhD, A. Bosly MD, PhD, N. Mounier

Read more

O.7 NOTCH1 c.7544–7545 delCt mutation identifies a subgroup of lymphocytic leukemia patients with poor outcome

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Franke , C. Herens , M. Jamar , N. Mongiovi , B. De Prijck MD, F. Lambert MD

Read more

P1.08 Hemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Sid MD, D. Dugauquier , B. De Prijck MD, C. Bonnet MD, PhD, Y. Beguin MD, PhD

Read more

P.07 Interim analysis of the randomized EORTC/ LYSA/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma

BJH - 2013, issue BHS Abstractbook, january 2013

P. André , E. Van den Neste MD, PhD, G. Verhoef MD, PhD, D. Bron MD, PhD, A. Van Hoof MD, PhD, P. Zachée MD, PhD, S. van Steenwegen , B. De Prijck MD, N. Straetmans MD, PhD, M. Maerevoet MD, D. Boulet , F. Offner MD, PhD, P. Pierre , V. Mathieux MD, PhD, P. Mineur MD, T. Connerotte , M. Federico , J. Raemaekers

Read more
Top